326 related articles for article (PubMed ID: 26922062)
1. Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
Shanmugam V; Margolskee E; Kluk M; Giorgadze T; Orazi A
Head Neck Pathol; 2016 Sep; 10(3):394-9. PubMed ID: 26922062
[TBL] [Abstract][Full Text] [Related]
2. Recurrent central nervous system Rosai-Dorfman disease with KRAS mutation: a case report.
Wang Q; Ren H; Zheng L; Wang J; Zhong D
Diagn Pathol; 2023 Feb; 18(1):21. PubMed ID: 36782249
[TBL] [Abstract][Full Text] [Related]
3. KRAS 117N positive Rosai-Dorfman disease with atypical features.
Jafri ZA; Reddy SP; Cassarino DS
J Cutan Pathol; 2021 Jan; 48(1):147-150. PubMed ID: 32974961
[TBL] [Abstract][Full Text] [Related]
4. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous Rosai-Dorfman disease with lack of BRAF-V600, KRAS or NRAS mutations: A reactive or neoplastic disorder?].
Machado I; Alcacer Fernández-Coronado J; Requena C; Través V; Latorre Martínez N; Ortega J; Requena L; Alcacer García J
Rev Esp Patol; 2022; 55(1):52-56. PubMed ID: 34980442
[TBL] [Abstract][Full Text] [Related]
6. How I Diagnose Rosai-Dorfman Disease.
Ravindran A; Rech KL
Am J Clin Pathol; 2023 Jul; 160(1):1-10. PubMed ID: 37167084
[TBL] [Abstract][Full Text] [Related]
7. Mediastinal Rosai-Dorfman Disease with KRAS mutation case report and literature review.
Zhang W; Fang L; Wang J; Ma X; Hu X; Liu W
J Cardiothorac Surg; 2024 Apr; 19(1):166. PubMed ID: 38561747
[TBL] [Abstract][Full Text] [Related]
8. Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.
Jacobsen E; Shanmugam V; Jagannathan J
N Engl J Med; 2017 Dec; 377(24):2398-2399. PubMed ID: 29236635
[No Abstract] [Full Text] [Related]
9. BRAF mutation leading to central nervous system rosai-dorfman disease.
Richardson TE; Wachsmann M; Oliver D; Abedin Z; Ye D; Burns DK; Raisanen JM; Greenberg BM; Hatanpaa KJ
Ann Neurol; 2018 Jul; 84(1):147-152. PubMed ID: 30014527
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease).
Paulli M; Bergamaschi G; Tonon L; Viglio A; Rosso R; Facchetti F; Geerts ML; Magrini U; Cazzola M
Br J Haematol; 1995 Oct; 91(2):415-8. PubMed ID: 8547085
[TBL] [Abstract][Full Text] [Related]
11. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status.
Abeykoon JP; Rech KL; Young JR; Ravindran A; Ruan GJ; Dasari S; Morlote DM; King RL; Rummage C; Zanwar S; Acosta-Medina AM; Tobin WO; Shah MV; Bennani NN; Vassallo R; Ryu JH; Koster MJ; Davidge-Pitts CJ; Witzig TE; Goyal G; Go RS;
JAMA Oncol; 2022 Dec; 8(12):1816-1820. PubMed ID: 36201194
[TBL] [Abstract][Full Text] [Related]
12. Sinus histiocytosis with massive lymphadenopathy: a "massive" misnomer.
Sardana D; Goyal A; Gauba K
Diagn Cytopathol; 2015 Apr; 43(4):315-9. PubMed ID: 25088489
[TBL] [Abstract][Full Text] [Related]
13. Rosai-Dorfman-Destombes disease - histiocytic disorder with inflammatory manifestation.
Adam Z; Adamová Z; Pour L; Řehák Z; Koukalová R; Král Z
Klin Onkol; 2022; 35(4):262-170. PubMed ID: 35989082
[TBL] [Abstract][Full Text] [Related]
14. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
[TBL] [Abstract][Full Text] [Related]
15. Rosai-Dorfman Disease between Proliferation and Neoplasia.
Elbaz Younes I; Sokol L; Zhang L
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358690
[TBL] [Abstract][Full Text] [Related]
16. NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.
Wu KJ; Li SH; Liao JB; Chiou CC; Wu CS; Chen CC
Biology (Basel); 2021 May; 10(5):. PubMed ID: 34063325
[TBL] [Abstract][Full Text] [Related]
17. The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus.
Ragotte RJ; Dhanrajani A; Pleydell-Pearce J; Del Bel KL; Tarailo-Graovac M; van Karnebeek C; Terry J; Senger C; McKinnon ML; Seear M; Prendiville JS; Tucker LB; Houghton K; Cabral DA; Guzman J; Petty RE; Brown KL; Tekano J; Wu J; Morishita KA; Turvey SE
Clin Immunol; 2017 Feb; 175():143-146. PubMed ID: 28043923
[TBL] [Abstract][Full Text] [Related]
18. Rosai-Dorfman disease in the central nervous system with two isolated lesions originated from a single clone: a case report.
Jin H; Yu Z; Tian T; Shen G; Chen W; Fan M; He Q; Xu F; Liu D
BMC Neurol; 2021 Sep; 21(1):352. PubMed ID: 34517832
[TBL] [Abstract][Full Text] [Related]
19. A Rare Case of Multiorgan Involvement of Rosai Dorfman Disease in an Elderly Female.
Waghmare RD
JNMA J Nepal Med Assoc; 2014; 52(195):955-7. PubMed ID: 26982675
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients.
Wang KH; Chen WY; Liu HN; Huang CC; Lee WR; Hu CH
Br J Dermatol; 2006 Feb; 154(2):277-86. PubMed ID: 16433797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
